Deep Dive: Page 11
Industry insights from our journalists
-
Reviewing Gilead's formidable 2015: A year marked by higher sales and new criticism
The biotech giant's sales continued to chug along in the midst of an industry-wide controversy over high drug prices. We examined the company's performance last year—and what it tells us about what to expect in 2016.
Ned Pagliarulo • Jan. 22, 2016 -
Cost control in the time of biopharma consolidation & globalization
Life sciences firms' wave of M&As and shifts abroad has catalyzed deals in other tranches of the supply chain, too.
Sy Mukherjee • Jan. 21, 2016 -
FDA
Behind the scenes at the FDA: Why they ultimately approved Addyi
In this week’s issue of the New England Journal of Medicine, Dr. Hylton Joffe and his colleagues at the FDA provide insight into the technical process of approving a drug—and some eye-opening facts about the controversial female libido pill Addyi.
Nicole Gray • Jan. 15, 2016 -
JPM16 winds down: Valeant's pricing promise, J&J's small deal focus, & a murky biopharma outlook
A (largely) less eventful JPMorgan Healthcare Conference and Biotech Showcase come to a close. Here's what you need to know.
Sy Mukherjee • Jan. 14, 2016 -
Warning letters reveal some of the FDA's biggest problems with Indian drugmakers
Nearly a third of the warning letters issued by the FDA's Center for Drug Evaluation and Research stemmed from violations of safe manufacturing practices at India-based facilities.
Ned Pagliarulo • Jan. 13, 2016 -
Cervical Health Awareness Month: How far we've come since Nixon declared war on cancer
When it comes to fighting cervical cancer, a 10-year-old drug is giving women new hope—and HPV vaccine marketers are trying to demystify the benefit-risk equation for physicians and parents.
Nicole Gray • Jan. 13, 2016 -
JPM16: An unprecedented cancer cure 'MoonShot,' Anthem threatens Express Scripts breakup
One of the boldest partnership and research efforts to be announced out of the JPMorgan Healthcare Conference so far also received a prime time boost from President Barack Obama's final State of the Union address on Tuesday night.
Sy Mukherjee • Jan. 13, 2016 -
JPM16 & BTS16: A dour start to biopharma's big week as stocks feel the pain
It's been a decidedly different mood so far at this year's JPMorgan Healthcare Conference and Biotech Showcase compared to last year's buoyant, nearly boisterous atmosphere. Here's what you need to know.
Sy Mukherjee • Jan. 12, 2016 -
3 key biopharma manufacturing stories to keep an eye on in 2016
From compliance issues abroad to the developmental challenges of groundbreaking new therapies, here are some of the most important issues to watch in the world of biopharma manufacturing in the coming year.
Sy Mukherjee • Jan. 7, 2016 -
A lesson in DTC: What happened when a Vogue contributor took Addyi for a test run
Spoiler alert: It worked for her (though not without some hiccups). And the Vogue story is a classic example of a form of DTC advertising with no pharmaceutical money involved.
Nicole Gray • Jan. 6, 2016 -
The year ahead: 11 execs & experts predict what's in store for biopharma in 2016
With a record-setting year behind us, we can only imagine what’s ahead for the industry in the coming months. Fortunately, industry execs and experts from Sanofi, Boehringer, Bain, amfAR, Novocure, and others shared some of their own predictions with BioPharma Dive.
Nicole Gray • Jan. 4, 2016 -
11 biopharma execs & experts look back on 2015: A record year for record-breaking
We spoke with bigwigs from Sanofi, the Biosimilars Council, Novocure, Accenture, Bain, amfAR, Boehringer Ingelheim, and more on what they considered the most significant events that drove biopharma this past year.
Nicole Gray • Dec. 22, 2015 -
Why Martin Shkreli's arrest won't take the heat off the biopharma industry
The battle over pricing controversies is here to stay, as evidenced by statements from lawmakers.
Sy Mukherjee • Dec. 18, 2015 -
Narcan is just the beginning: Unleashing the power of opioid antagonism
We spoke with Roger Crystal, CEO of Lightlake Therapeutics, about new ways to use old drugs to address opioid overdose and other addiction-related disorders.
Nicole Gray • Dec. 18, 2015 -
How biopharma and media are reacting to Shkreli's arrest
Responses ranged from open glee to warnings to the biopharma industry that its pricing practices won't be leaving the spotlight.
Sy Mukherjee • Dec. 17, 2015 -
Shkreli's latest acquire-and-hike antics spotlight review voucher critics' biggest fears
Biopharma's bête noire wants to use his new perch as CEO of KaloBios to make the 1970s-era Chagas disease treatment benznidazole cost as much as next-gen hep C drugs like Sovaldi—and to get a valuable review voucher in the process.
Sy Mukherjee • Dec. 15, 2015 -
A lead researcher and a Boehringer SVP on the drumbeat of innovation in oral anticoagulants
We spoke with the two experts to better understand how innovation can thrive even when things seem to be headed south.
Nicole Gray • Dec. 11, 2015 -
Inside the bold new fight for an HIV cure: An exclusive interview with amfAR CEO Kevin Robert Frost
Seven years ago, Frost faced calls for his resignation over his suggestion that an HIV cure was an attainable goal. This week, his group announced the establishment of a research institute which he compares to NASA and the Manhattan Project that is 100% focused on this precise mission.
Nicole Gray • Dec. 4, 2015 -
The 5 pharma vets and 3 newcomers that made BCG's '50 most innovative' firms list
The Boston Consulting Group's 10th annual ranking of the most innovative companies included some new names from biopharma, including Gilead, Biogen, and Roche.
Ned Pagliarulo • Dec. 4, 2015 -
World AIDS Day: PrEP uptake main hurdle to 2030 eradication goal as Obama unleashes action plan
The president on Tuesday outlined a federal action plan for tackling HIV/AIDS which endorsed full access to PrEP for at-risk individuals. Will his remarks help increase use of the controversial therapy?
Nicole Gray • Dec. 1, 2015 -
How pharma is trying to get patients to stay on their meds—and out of the hospital
Non-compliance to treatment regimens costs the U.S. healthcare system $300 billion per year and is a body blow to patient health. Here's how hospitals and pharma firms are trying to change that dynamic.
Sy Mukherjee and Jeff Byers • Nov. 30, 2015 -
So your biopharma got fined millions by the feds—Where does that money go?
Major players in the industry regularly settle federal suits with hefty payouts. But could that cash be put to better use by the government—and are fines even an effective way of ensuring ethical behavior?
Sy Mukherjee • Nov. 25, 2015 -
The 'Pfallergan' fallout: Reactions to—and questions for—the biggest healthcare deal of all time
Lawmakers, presidential contenders, and regulators are already preparing to step up the pressure on Pfizer and Allergan, while investors and industry observers still have plenty of questions about how the combined entity will ultimately be structured.
Sy Mukherjee • Nov. 24, 2015 -
How biopharma companies can thrive in the era of megamergers and shrinking budgets
We spoke with James Crowley at Accenture Life Sciences about what it takes to not only survive, but to shine, in a hyper-competitive market.
Nicole Gray • Nov. 24, 2015 -
Why marketers think they'll win in doctors' new war on DTC drug ads
The American Medical Association's proposed ban on direct-to-consumer prescription drug ads threatens to end a $4.5B ad category and is being slammed by pharma companies, and particularly marketers.
Natalia Angulo • Nov. 20, 2015
Previous
